Background: Brain metastasis, with an incidence of more than 30%, is a common
complication of non-small cell lung cancer (NSCLC). Therefore, there is an urgent need for …

Background Patients with non-small cell lung cancer (NSCLC) who develop brain
metastases (BM) have a poor prognosis. This study aimed to construct a clinical prediction …

Objective: To investigate the effects of different treatment modes on the survival of patients
with non-small cell lung cancer (NSCLC) brain metastases, and to evaluate the clinical …

Background The current published prognosis models for brain metastases (BMs) from
cancer have not addressed the issue of either newly diagnosed non–small-cell lung cancer …

2032 Background: 30-50% of patients with non-early NSCLC will eventually develop BM,
with a median survival of less than one year from BM diagnosis. There are no widely …

Background Clinical biomarkers for brain metastases remain elusive. Increased availability
of genomic profiling has brought discovery of these biomarkers to the forefront of research …

Background The prognosis of non-small cell lung cancer (NSCLC) with brain metastases
(BMs) had been researched in some researches, but the combination of clinical …

Background Throughout the course of non-small cell lung cancer (NSCLC), a lot of patients
would develop brain metastasis (BM) associated with the poor prognosis and high rate of …

Objective This study aims to establish and validate a new nomogram for predicting brain
metastasis from lung cancer by integrating data. Methods 266 patients diagnosed as lung …

Brain metastases are the most common tumors of the central nervous system (CNS).
Incidence rates vary according to primary tumor origin, whereas the majority of the cerebral …